To Name :
To Email :
From Name :
From Email :
Comments :

Vasomotor symptoms: Managing the transition from perimenopause to postmenopause

October 2008 · Vol. 08, No. 10(Suppl)

FACULTY

James McGregor, MD, CM
Speaker Bureau: Ther-Rx Corporation
Consultant: Genzyme Corporation and Ther-Rx Corporation

Lee P. Shulman, MD
Speaker Bureaus: Barr Pharmaceuticals, Inc., Bayer, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Ortho-McNeil-Janssen, Inc., Roche Laboratories, Schering-Plough Corporation, Ther-Rx Corporation, and Wyeth Pharmaceuticals
Consultant: Barr Pharmaceuticals, Inc., Bayer, Johnson & Johnson, Ortho-McNeil-Janssen, Inc., and Schering-Plough Corporation
Research Grants: Barr Pharmaceuticals, Inc.

Bagirathy Ravishankar, PhD, Scientific Director, The Chatham Institute
No real or apparent relationships to disclose

Frank Siri, PhD, Medical Writer, The Chatham Institute
No real or apparent relationships to disclose

Daniel Duch, PhD, Medical Director, The Chatham Institute
No real or apparent relationships to disclose

Release date: October 1, 2008
Expiration date: September 30, 2008
Estimated time to complete: 1.5 hours

This activity is sponsored by The Chatham Institute and supported by an educational grant from Ther-Rx Corporation. This supplement was submitted by The Chatham Institute. It was edited and peer reviewed by OBG Management.

Learning objectives

At the conclusion of this activity, participants should be able to:
• Recognize menopause-related vasomotor symptoms to establish the clinical stages of menopausal transition
• Discuss the underlying physiology of climacteric symptoms
• Outline the various treatment options that are available for women with vasomotor symptoms and the risks/benefits associated with each
• Evaluate the evidence-based data on hormone therapy and formulate a patient-specific treatment plan for menopausal vasomotor symptoms
• Counsel women and their partners on the risks/benefits of alternative therapies to treat menopausal vasomotor symptoms

Accreditation and designation

The Chatham Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Chatham Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Chatham Institute LLC is an approved provider of continuing nursing education by the New Jersey State Nurses Association (NJSNA), an accredited approver by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation, provider number P175-11/2006-2009.

The Chatham Institute LLC is approved by the California Board of Registered Nursing (CBRN), provider number CEP 12433.

This activity is approved for 1.5 contact hours.

Disclaimer:
Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or The Chatham Institute LLC.

Disclosure
It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty who affect the content of medical education activities sponsored by The Chatham Institute are required to disclose to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose discussion of off-label uses in their presentations. Faculty not complying with the disclosure policy are not permitted to participate in the educational activity.

All program content has been peer reviewed for balance and any potential bias. The conflict of interest resolution process aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

Sponsership and Support
This activity is sponsored by The Chatham Institute and supported by an educational grant from Ther-Rx Corporation.

This supplement was submitted by The Chatham Institute. It was edited and peer reviewed by OBG Management.


Continue to Article

Did you miss this content?
Does a family history of both breast and prostate cancer (vs breast only) put a woman at greater risk for future breast cancer?